NCT02655549已完成1 期
A Phase 1a Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study Assessing Safety and Immunogenicity of Px563L and RPA563 Administered by Intramuscular Injection in Healthy Adult Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfenex, Inc
- 入组人数
- 54
- 试验地点
- 2
- 主要终点
- Adverse events (AE) and adverse events of special interest (AESI) for vaccines
研究概览
简要总结
The trial investigates Px563L and RPA563, two formulations of a novel anthrax vaccine.
详细描述
This is a Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of Px563L or RPA563 administered intramuscularly. All subjects will be followed for safety and tolerability for 393 days after the initial vaccination. Immunogenicity analyses will be performed for up to 182 days, including an interim analysis based on Day 70 results, after the initial vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Willing and able to read and understand the consent process and sign an informed consent form (ICF).
- •Females or males between the ages of 18 and 55, inclusive, at the time of informed consent.
- •Healthy or with stable medical conditions not requiring continuous medication.
排除标准
- •Female subjects who are pregnant or breastfeeding.
- •A history of anthrax disease or receipt of an anthrax vaccine at any time in the past, exposure to or infection with B. anthracis, or has received any investigational anthrax vaccine or treatment (e.g., monoclonal antibodies, anthrax immune globulin).
- •Positive test for human immunodeficiency virus (HIV), hepatitis C or hepatitis B (surface antigen).
- •History of any malignant neoplasm or receipt of anti-neoplastic agents within the last 5 years, with the exception of adequately treated, localized or in situ non-melanoma of the skin (e.g., basal cell carcinoma) or of the cervix.
- •History of immunodeficiency, chronic illness requiring continuous or frequent medical intervention, autoimmune disease, bleeding disorder, hemoglobinopathy, prior solid organ or bone marrow transplant, or any known history in the past 5 years of cardiac disease.
- •Evidence of alcohol abuse (i.e., requiring treatment) or substance abuse (i.e., any use of illicit drugs) within 6 months prior to screening.
- •History of severe allergy (e.g., anaphylaxis) to latex or rubber.
- •Subjects who have significant scarring, tattoos, abrasions, rash, or other skin abnormality at the planned vaccination site that could interfere with evaluation of injection site..
- •Use of any systemic steroids or other immunosuppressive agents within 2 years prior to screening; or use of topical, intranasal, or inhaled corticosteroids for ≥10 consecutive days within 1 year prior to screening.
- •Administration of any licensed vaccines within 30 days prior to screening.
- •History of anaphylaxis or other serious adverse reaction to vaccines.
- •Donation or loss of >500 mL of blood or donation of plasma within 2 months of screening, or recipient of blood or blood products within 2 months of screening.
- •Present or former member of US military or reservist who may have or will receive the licensed anthrax vaccine, or who has served in any military arena from January 1990 through present time.
- •May be at risk for exposure to anthrax or may be required to receive the licensed anthrax vaccine (e.g., postal workers).
- •Has previously participated in any anthrax vaccine or anti-protective antigen (PA) monoclonal antibody clinical trial.
结局指标
主要结局
Adverse events (AE) and adverse events of special interest (AESI) for vaccines
时间窗: 393 days
次要结局
- Anthrax toxin neutralizing antibody (TNA) 50% neutralization factor (NF50) value(182 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate VaccinesAnthrax InfectionNCT01979406Emergent BioSolutions120
已完成
1 期
A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus VaccineRotavirus InfectionNCT01764256PATH48
已完成
2 期
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsAnthraxNCT01770743Emergent BioSolutions168
已完成
3 期
Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in ChinaHaemophilus Influenzae Type b (Hib) InfectionNCT01044316Novartis Vaccines670
尚未招募
3 期
Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)RabiesNCT05969626Ningbo Rongan Biological Pharmaceutical Co., Ltd.2,460